Genetic Engineering & Biotechnology News
The biosimilars market is growing rapidly. The global market, currently valued at around $5 billion, is expected to exceed $28 billion by 2020. Over the past two years, seven biosimilars have been approved by the FDA, including two each for the anti-inflammatory drugs adalimumab and infliximab, and one each for filgastrin, etanercept and bevacizumab.
If Europe is a guide, the sales of biosimilars will continue to grow in the US, as physicians increase their rate of prescription, and patients become more comfortable using biosimilars.